Last Updated: May 2, 2026

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expire, and when can generic versions of Norepinephrine Bitartrate In 0.9% Sodium Chloride launch?

Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp, Inforlife, and Long Grove Pharms. and is included in three NDAs. There are ten patents protecting this drug.

This drug has forty-nine patent family members in forty countries.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 0.9% Sodium Chloride

A generic version of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
  • What are the global sales for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
  • What is Average Wholesale Price for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
Summary for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is protected by ten US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Long Grove Pharms NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214628-003 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Long Grove Pharms NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214628-003 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Long Grove Pharms NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214628-003 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Long Grove Pharms NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214628-003 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Baxter Hlthcare Corp NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214313-004 Feb 6, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Long Grove Pharms NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE norepinephrine bitartrate SOLUTION;INTRAVENOUS 214628-001 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE around the world.

Country Patent Number Title Estimated Expiration
Moldova, Republic of 4628 ⤷  Start Trial
Spain 2663817 ⤷  Start Trial
Taiwan 201620499 Process for producing a stable low concentration, injectable solution of noradrenaline ⤷  Start Trial
Jordan 3552 عملية لإنتاج محلول نورادرينالين ذو تركيز منخفض مستقر قابل للحقن (Process for producing a stable low concentration, injectable solution of noradrenaline) ⤷  Start Trial
Nicaragua 201600118 ⤷  Start Trial
European Patent Office 3110399 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.